| Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JD Soumerai, ... Blood cancer journal 10 (7), 74, 2020 | 133 | 2020 |
| Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse A Kumar, F Sha, A Toure, A Dogan, A Ni, CL Batlevi, MLM Palomba, ... Blood Cancer Journal 9 (6), 50, 2019 | 100 | 2019 |
| Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JF Gerecitano, ... European Journal of Cancer 126, 78-90, 2020 | 25 | 2020 |
| Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma A Kumar, Z Ying, A Alperovich, A Dogan, P Hamlin, C Moskowitz, ... Haematologica 104 (4), e163, 2019 | 24 | 2019 |
| Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors Z Li, X Wu, Y Zhao, Y Xiao, Y Zhao, T Zhang, H Li, F Sha, Y Wang, L Deng, ... MedComm 2 (1), 60-68, 2021 | 21 | 2021 |
| miR-183 potentially inhibits NF-κB1 expression by directly targeting its 3′-untranslated region F Sha, S Wu, H Zhang, X Guo Acta Biochim Biophys Sin 46 (11), 991-996, 2014 | 10 | 2014 |
| Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or … P Ghione, E Joffe, N De Paola, T Mainardi, SJ Noor, S Bobillo, ... Journal of Clinical Oncology 38 (15_suppl), 8062-8062, 2020 | 5 | 2020 |
| Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines Y Xiao, H Xu, W Guo, Y Zhao, Y Luo, M Wang, Z He, Z Ding, J Liu, L Deng, ... Molecular biomedicine 1, 1-26, 2020 | 3 | 2020 |
| Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma F Sha, M Okwali, A Alperovich, PC Caron, L Falchi, A Hamilton, ... Blood Cancer Journal 12 (2), 29, 2022 | 1 | 2022 |
| Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. H Huang, XY Li, HM Hong, Z Wang, X Fang, F Li, C Peng, Q Ren, F Sha, ... Journal of Clinical Oncology 36 (15_suppl), 7560-7560, 2018 | 1 | 2018 |
| CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMA F Sha, M Okwali, A Alperovich, PC Caron, L Falchi, A Hamilton, ... Hematological Oncology 39, 2021 | | 2021 |
| PET-Based Staging Reduces the Prognostic Impact of Early Disease Progression in Patients with Follicular Lymphoma C Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JF Gerecitano, ... | | 2019 |
| IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, P Hamlin, ... Hematological Oncology 37, 152-153, 2019 | | 2019 |
| Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical … T Lin, F Sha, H Huang, Z Wang, S Lin, X Li, H Hong, X Fang, F Li, C Peng, ... Journal of Clinical Oncology 36 (15_suppl), 7553-7553, 2018 | | 2018 |
| Chinese Guidelines on the Diagnosis and Treatment of Lymphoma PC Ma J, Shuang Y, Wu G, Zhu J, Zhu H, Li Z, Qiu L, Shen L, Su L, Chen J ... | | 2017 |
